Scienture Holdings, Inc. (SCNX)
$
0.4
-0.01 (-2.50%)
Key metrics
Financial statements
Free cash flow per share
-0.5862
Market cap
6.1 Million
Price to sales ratio
9.3327
Debt to equity
0.0245
Current ratio
0.1933
Income quality
0.5503
Average inventory
117.3 Thousand
ROE
-0.2563
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
TRxADE HEALTH, Inc. is a health services IT company based in Tampa, Florida. The company specializes in providing an online web-based platform that facilitates the buying and selling of brand, generic, and non-drug products and services. This platform serves licensed pharmaceutical wholesalers and connects them with government organizations, hospitals, clinics, and independent pharmacies, thereby enhancing the accessibility and distribution of healthcare products and services. The stock is affordable at $0.89 suitable for budget-conscious investors. With a market capitalization of $6,097,914.00 the company is classified as a small-cap player. It is a key player in the Medical - Healthcare Information Services industry, contributing significantly to the overall market landscape. The stock has a low average trading volume of 1,163,776.00 indicating lower market activity. Additionally, it belongs to the Healthcare sector, driving innovation and growth.
Is Scienture Holdings, Inc. (SCNX) a good investment?
Investing in Scienture Holdings, Inc. (SCNX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Scienture Holdings, Inc. (SCNX)'s stock forecast?
Analysts predict Scienture Holdings, Inc. stock to fluctuate between $0.37 (low) and $3.17 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Scienture Holdings, Inc.'s market capitalization?
As of 2026-03-06, Scienture Holdings, Inc.'s market cap is $6,097,914, based on 15,391,000 outstanding shares.
Does Scienture Holdings, Inc. pay dividends?
Scienture Holdings, Inc. pays dividends. The current dividend yield is 126.84%, with a payout of $1.50 per share.
How can I buy Scienture Holdings, Inc. (SCNX) stock?
To buy Scienture Holdings, Inc. (SCNX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SCNX. Place an order (Market, Limit, etc.).
What is the best time to invest in Scienture Holdings, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Scienture Holdings, Inc. stock ever split?
Scienture Holdings, Inc.'s last stock split was 1:15 on 2023-06-22.
How did Scienture Holdings, Inc. perform in the last earnings report?
Revenue: $136,643 | EPS: $2.69 | Growth: -111.52%.
Where can I find Scienture Holdings, Inc.'s investor relations reports?
Visit https://www.trxadehealth.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Scienture Holdings, Inc.?
You can explore historical data from here
What is the all-time high and low for Scienture Holdings, Inc. stock?
All-time high: $9.55 (2024-10-29) | All-time low: $0.37 (2026-02-23).
What are the key trends affecting Scienture Holdings, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
a month ago
Company highlights accelerating access and revenue growth for ARBLI ™ and confirms REZENOPY ™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million
defenseworld.net
a month ago
Scienture Holdings, Inc. (NASDAQ: SCNX - Get Free Report) saw a large increase in short interest in January. As of January 15th, there was short interest totaling 3,504,653 shares, an increase of 46.2% from the December 31st total of 2,397,102 shares. Currently, 11.0% of the company's stock are sold short. Based on an average trading volume
globenewswire.com
2 months ago
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that the United States Patent and Trademark Office has issued U.S. Patent No.
feeds.benzinga.com
2 months ago
New US patent strengthens protection for Rezenopy, the FDA-approved 10 mg naloxone nasal spray.
globenewswire.com
3 months ago
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided an update on the commercial launch of REZENOPY®.
feeds.benzinga.com
3 months ago
Scienture stock is climbing after the company partnered with BlinkRx to expand national access to its new FDA-approved liquid losartan therapy, Arbli.
globenewswire.com
3 months ago
U.S. Losartan market totals $245M annually with 71M prescriptions COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, and Blink Rx LLC (“BlinkRx”), one of the most advanced patient access platforms for branded medications, today announced a strategic collaboration to expand national access to Arbli™, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium.
seekingalpha.com
3 months ago
Scienture Holdings, Inc. (SCNX) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
globenewswire.com
3 months ago
COMMACK, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that management will be participating in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - 10th, 2025.
globenewswire.com
4 months ago
Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli ™ , the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertension COMMACK, NY, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the third quarter ended September 30, 2025.
See all news
